that identification through the open 2-compartment model is certainly related to the small number of late time-points. We therefore think that mitoxantrone pharmacokinetics is generallv best described by an open 3-compartment model. Clearance values showed that there was no saturation in mitoxantrone elimination. es-en at the highest doses. Terminal elimination half-life was probably underestimated because of the lack of late time-points in some kinetics. The half-life is long for patients receiving high-dose mitoxantrone (mean salue u-as 50 h) and it u-ould be hazardous to perform BMT too earlv after mitoxantrone infusion. Mitoxantrone metabolites u-ere detected in the plasma of fixe patients receiving high-dose mitoxantrone and in one with hepatic impairment.
The anthracenedione drug. mitoxantrone (Novantronez) . is a svnthetic analogue of anthracyclines which is active in the treatment of leukaemia. 1 mphoma. breast cancer and ovarian cancer (Smith. 1983 : Zee-Cheng & Cheng. 1983 : Shenkenberg & Von Hoff. 1986 : Lenk et al.. 1987 . Its mechanism of action involves DNA intercalation, and inhibition of topoisomerase II activity. The involvement of mitoxantrone in multidrug resistance remains unclear and its cross resistance with doxorubicin (adriamycin) is only partial. Moreover. its toxic side effects are weaker than those of doxorubicin. In particular. the cardiotoxicitv of mitoxantrone is much less pronounced. alloWing the use of a relatively higher dosage than that of anthracyclines. However, the haematologic toxicity of mitoxantrone is severe. The drug therefore seemed to be a good candidate for high-dose chemotherapy because of the possibility of associating an intercalating agent with the alkylating drugs. cyclosphosphamide and melphalan. Autologous bone marrow transplantation (ABMT) was associated to prevent haematologic toxicity.
Mitoxantrone pharmacokinetics have been described in different studies with conventional dosages (10-12 mg m -) by either an open two- (Reynolds. et al.. 1981 : Savaraj et al.. 1982a 1982b; Larson et al.. 1987) or an open three-compartment model (Hulhoven et al.. 1984; Ehninger et al.. 1985a : 1986 : Smyth et al.. 1986 : Wilkinson et al.. 1986 : in some studies it has been described with both models (Alberts et al.. 1983; 1985a; van Belle et al.. 1986) . Besides the large interpatient variability described by all these authors. the pharmacokinetic parameters were very different from one France) and was dissolved in 100 ml of 0.9% NaCl solution or 5% dextrose solution. The infusion rate was constant and controlled by an electric pump.
For the conventional dose. the administration protocol was 12mgm--every 21 days which corresponds to a total dose of 14-18 mg in a 10-min infusion (patient group I) except for patient B who received the second course 7 days after the first one. For the high-dose protocol (group II), day 0 was the day of the ABMT. Mitoxantrone was administered at the dose of 12 mg m day-' in a 10-min infusion on day -7 for patient 1, and on day -9, day -8 and day -7 for patient 2 (see Table II ). For the remaining patients in group II, mitoxantrone was administered on day -7 in a single 1-h infusion at increasing doses, i.e. 30. 33, 40 mg m-(total dose of 45, 50 and 60 mg for the tested patients). Mitoxantrone was associated with the other anti-cancer drugs usually used in the BMT unit for high-dose chemotherapy: cyclophosphamide at the dose of 60 mg kg-' day-', on days -5 and day -4, and melphalan: 140mgm-2 day-', on day -2.
For the patients of group II, other medications consisted of oral antibioprophylaxis with unabsorbed drugs (cephamandole, colistin, amphotericin, tobramycin) and of an antiemetic drug (chlorpromazine, 20 -30 mg daily). Blood samples were of 5 or 10 ml. They were immediatelv centrifuged at 1000 x g for 10 min. Plasma was separated and collected in polypropylene tubes containing 1 mg of ascorbic acid used as antioxidant. Tubes were vortexed for 30 s and stored at -20C until analI sis. For patient B. samples were drawn during the 1 st. the 2nd and the 5th courses.
Anali sis Plasma mitoxantrone concentrations were measured with a high-performance liquid chromatography (HP-LC) assay previously described bv Payet et al. (1988) and slightly modified to obtain a higher sensitivity (Catalin et al.. 1988) . This technique allowed separation of both mitoxantrone and its two major metabolites (mono-and dicarboxylic acid derivatives) in various biological fluids. and plasma quantitation of mitoxantrone ( Figure 1 ). Metabolites were identified according to their retention time compared with those of standards provided by Lederle Laboratories.
To inject a larger amount of plasma without clogging the HPLC system. plasma proteins were precipitated with a mixture of 300 sulphosalicyclic acid -methanol (50 -50°0). The detection limit of unchanged mitoxantrone in plasma was 0.5 ngml-1.
Since the two main metabolites were not available in large amounts as standards. they were assayed in mitoxantrone equivalents as performed by others (Ehninger et al.. 1985a; 1986 (Figure 2 ). The concentration of these metabolites estimated in mitoxantrone equivalents was much lower than that of unchanged drug. In patient 5. the monocarboxylic acid derivative reached 25.2 mitoxantrone equivalents 40 mn after the end of infusion whereas the dicarboxylic acid derivative reached 27.24 mitoxantrone equivalents 2 h after the end of the infusion. Metabolites rapidly disappeared from plasma and they could not be quantified after the first day because of their low plasma concentrations. (Mulder et al.. 1989) .
The determination of a long VI (50.26 ± 20.62 h) . and the detection of plasma mitoxantrone concentrations of about 1 ng ml' up to 7 days after a high-dose protocol are verv important in the case of BMT. In vitro mitoxantrone LDio for granulocyte-macrophage progenitor cells (CFU-GM) has been described as about 10 ng ml-' for a 6-h incubation, and about 2.5 ng ml1 for a 7-day incubation (Fountzillas et al.. 1986 ). These concentrations are higher than those detected at day 0 (range: 0.6-1.0 ng ml-'). In our series. no patient had a delayed haematopoietic recovery. Indeed. it would be hazardous to perform the transplantation too early after mitoxantrone infusion. (Savaraj et al.. 1982a; Alberts et al.. 1985a; Ehninger et al.. 1986; Mulder et al.. 1989) .
Interindividual variability
The case of patient A is remarkable in group I. This woman with a marked hepatic impairment due to metastases had the highest plasma mitoxantrone concentration of group I, probably because of deficient hepatic elimination.
Metabolites
It is now well known that mitoxantrone is metabolized into two main metabolites identified as the mono-and the dicar- boxylic acid derivatives, and into a group of unidentified metabolites which are more polar than the other ones (Chiccarelli et al., 1986 : Richard et al., 1991 . The first two seem to be inactive on murine leukaemia P388 (Chiccarelli et al., 1986) . These metabolites were most often descnrbed in the urine of patients (Ehninger et al., 1985a; 1986; Chiccarelli et al., 1986) and by Ehninger et al. in plasma (1985a; 1985b; 1986) in a single patient after a 14mgm-' mitoxantrone infusion. As others. we did not observe plasma metabolites in most patients receiving conventional drug dosage: but we did in four of five patients who received more than 30 mg m of mitoxantrone in a 1 h infusion (patients 3. 4. 5. 7). in the patient receiving three daily doses of 12 mg m-(patient 2). and in one patient in group I who had a severe hepatic impairment (patient A) .
Since the liver is the major organ of mitoxantrone uptake (Alberts et al.. 1983 (Alberts et al.. : 1985b Roboz et al.. 1984 : Stewart et al.. 1986 . and since human hepatocytes in vitro produce a significant amount of metabolites (Richard et al.. 1991) it is highly likely that metabolites are produced mainly by the liver in humans.
The presence of metabolites in patient A may be due to the fact that her mitoxantrone plasma levels were higher than those of other patients of this group or because their excretion was lowered. In the other patients. there is no saturation of mitoxantrone elimination. We also know that its in vitro biotransformation by hepatocytes is not saturable even at very high concentrations (10 jig ml-) (Richard et al.. 1991);  hence this phenomenon is certainly only connected with higher mitoxantrone plasma concentrations. These observations further demonstrate the role of the liver in both drug metabolism and elimination in vivo.
Conclusion
This work (i) confirms the large interpatient variability. even in the high-dose group which was more homogeneous. Besides, it shows (ii) that there is no saturation in mitoxantrone elimination in patients receiving 60 mg, (iii) that terminal plasma half-life is generally long (30-60 h). and (iv) that plasma metabolites are frequently observed in patients receiving high-dose infusions. With regard to pharmacokinetic data, mitoxantrone can be used in high-dose chemotherapv before bone marrow transplantation. Moreover. because of the long elimination half-life of mitoxantrone. a 1-week decay between the last drug infusion and the transplantation has to be respected.
